DBI has been featured in the media. Read what others have to say about how we use breath analysis for diagnosis and patient treatment.
Press Releases
Deep Breath Intelligence Teams with HTEC Group and Effectum Medical to Accelerate the Launch of CE-marked device under IVDD
DBI is pleased to announce that Emergo will become its authorised DBI-EPIbreath® representative in the European Community, helping Deep Breath Intelligence (DBI) to speed up their time to market and move boundaries in therapeutic drug monitoring (TDM) for people living with epilepsy.
DBI, a MedTech company unleashing the huge potential of exhaled breath analysis through machine learning, has selected HTEC Group and Effectum Medical as primary innovation facilitators to help them achieve greater speed in meeting both software and documentation requirements to ensure IVDD compliance of their medical software, DBI-EPIbreath®. DBI-EPIbreath® is a unique easy-to-apply breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication valproic acid to aid patient management. Fast diagnosis and quick medication decisions are essential for epileptic seizure control. Standard TDM approaches are based on measuring drug concentrations in plasma or serum, but this has limitations and can take several days to turn around results. DBI-EPIbreath® is the first non-invasive test, CE-marked under IVDD, that allows real-time measurement of the total and free concentrations of valproic acid in a breath sample, delivering results in just 10 minutes.
Considering a very strict regulatory deadline that DBI had to meet to make DBI-EPIbreath® compliant, they approached HTEC to help them speed up their product launch considering regulatory requirements of IVDD in conjunction with Effectum Medical, the official legal manufacturer of the medical device. Effectum Medical gathered a team of professionals with extensive regulatory and compliance domain knowledge to help HTEC to meet the regulatory requirements for medical device software development and DBI to achieve product launch in a record time of just 6 months, which would normally take 12 to 18 months by any other standard.
“Every medical venture or initiative would like a speedy launch, but only the right skill set and partnership with a client can deliver. It requires teams that work well together, understand regulatory expectations and demands, and deliver in a way that aligns with product-market fit. HTEC’s deep understanding of MedTech space and unique approach to determining a direct-line path to getting a market-oriented medical product certified was mission-critical in the process of accelerating the launch of this revolutionary medical device. This success is a testimony to HTEC’s ability to develop innovative and life-changing medical software and hardware products that enable faster innovation in a healthcare space.” — Sava Marinkovich, Head of HealthTech at HTEC Group
“The project with DBI and HTEC is a great proof of Effectum Medical’s vision "We make innovation happen!" In everything we do, the focus is on the entrepreneur and the innovative medical device product. Our mission is to accelerate market access for start-ups to save time and money, which are both critical factors for their success. With our regulatory expertise and the quality management system as service, we are the ideal sparring partner to avoid typical pitfalls on the way of product development and regulatory approval. Within an incredibly short time we achieved CE mark and enabled a perfect interaction between the three key stakeholders – DBI as innovator, HTEC as software supplier and Effectum Medical as legal manufacturer. We are proud that DBI has chosen us as its legal manufacturer. Our joint journey continuous and we will ensure their compliance with our lean post-launch processes.” — Karina Candrian, CEO of Effectum Medical
“This is a major milestone for us as a startup that has invested more than 45 years in researching and developing this revolutionary method. And this is only the start. This initiative is a critical step in our mission to broaden the range of medical application for early disease testing in the years to come. We really enjoyed the close and professional collaboration with Effectum Medical and the HTEC team which allowed us to identify early critical topics for CE mark, accomplish this project on time and within the targeted budget.” — Christian Zwicky, Chief Executive Officer at Deep Breath Intelligence
HTEC, Effectum Medical and DBI will continue to collaborate on future projects with the ambition to develop a broad range of products in different disease areas to take precision medicine to the next level and improve people’s health.
About Deep Breath Intelligence
Deep Breath Intelligence is a MedTech company unleashing the huge potential of analyzing exhaled breath by applying machine learning algorithms. They provide non-invasive solutions for early diagnosis of diseases and therapeutic drug monitoring – enabling better treatment by precision medicine. Their first product, DBI-EPIbreath®, is a test for drug monitoring in epilepsy which is CE-certified under IVDD. They are working hard on developing a broad range of products in different disease areas to take future precision medicine to the next level and improve people’s health.
About HTEC Group
HTEC Group is a global digital product development and engineering services firm powering the technological evolution of the world's most impactful organizations – from disruptive startups to Fortune 500 companies. Founded in 2008 in Belgrade, Serbia, the company is now headquartered in San Francisco, with more than 2,000 experts spread across the traditional engineering hotspots of Central and Southeast Europe and consulting, innovation, and product design offices in Silicon Valley, New York, and London. With the highest level of expertise and extensive experience in a multitude of business domains – including Healthcare, Retail, Transportation and Smart Mobility, Logistics, FinTech, Green Energy, Media, and Deep Technology – HTEC is both an ideal technology partner for its clients and the ultimate growth platform for its employees.
About Effectum Medical
Effectum Medical is a Swiss leading MedTech service partner who accelerates time to market by offering an outsourced quality management system to “buy or rent”. Innovators can trust in a thoroughly audited and certified infrastructure to gain speed and significantly reduce costs. A team of Medical Device Experts combines hands-on support with state-of-the art advise to make the product development a success. The vision “We make innovation happen!” comes true by supporting start-ups, medical doctors, SME’s and international pharmaceutical companies or suppliers on their MedTech venture. In addition, Effectum Medical collaborates with leading Swiss and European Healthcare incubators and accelerators as coaches, judges, and experts.
Epilepsy patients set to benefit from non-invasive, real-time molecular breath analysis
Deep Breath Intelligence is pleased to announce the launch of DBI-EPIbreath®, a simple breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication (ASM) valproic acid to aid patient management. This innovative diagnostics tool will be showcased at the European Epilepsy Congress taking place in Geneva, Switzerland, from the 9th to the 13th of July.
Fast diagnosis and quick medication decisions are essential for epileptic seizure control. Standard therapeutic drug monitoring (TDM) approaches are based on measuring drug concentrations in plasma or serum, but this has limitations, and it can take several days to turn around results. DBI-EPIbreath® is the first CE-IVDD certified, non-invasive test that allows real-time measurement of the total and free concentrations of valproic acid in a breath sample, delivering results in just 10 minutes. The test combines secondary electrospray ionization-high resolution mass spectrometry (SESI-HRMS) with sophisticated bioinformatic tools to assist in the management of ASM dosing regimens. Patients simply exhale into a SESI-HRMS instrument, and the data is analyzed using machine learning algorithms. DBI-EPIbreath® also predicts the likelihood – low, moderate or high – of drug response, as well as providing a side effects risk score, helping clinicians to identify whether a patient is likely to benefit from the treatment and/or suffer from unwanted side effects.
Tests can be performed as often as necessary, making the technique an ideal fast and non-invasive diagnostics tool to blood testing. It is particularly advantageous for pediatric patients – where blood draws can be challenging – or if more frequent testing is required for any reason, such as individuals who are non-responsive or develop pharmaco-resistance. This machine learning approach has potential to be expanded to include other ASMs in the future, enabling many more people with epilepsy to benefit from fast, non-invasive TDM.
Press Publications
Ein Atemtest könnte Epileptikern zukünftig die Blutabgabe ersparen - Deep Breath Intelligence in the Luzerner Zeitung
Many thanks to the Luzerner Zeitung for the interesting article about our technology to take future precision medicine to the next level and improve people’s health.
Read the full article - in German, only - here
Deep Breath Intelligence wins *zünder Award 2023
Deep Breath Intelligence won the *Zünder Award 2023. Read the full press publication in start-up ticker here: https://www.startupticker.ch/en/news/deep-breath-intelligence-holt-sich-zuender-award-2023. Thanks for the nice article!
DBI-EPIbreath® in the epiKurier
The epiKurier published an article about DBI-EPIbreath®. Read more about how DBI-EPIbreath® allows to measure the concentration of valproic acid non-invasively in people living with epilepsy in the current edition. Thank you for the nice publication.
The epiKurier is a joint publication of the Epilepsie Elternverband e.V. and the Landesverband Epilepsie Bayern e.V. It is their mission to inform people living with epilepsy, their families and everybody who wants to learn more about epilepsy. Keep up the great work!
DBI-EPIbreath® article in the epiKurier (in German)
How to revolutionize the early detection of diseases
The interest is growing more and more! The day after we have been awarded as “Zug Young Entrepreneur 2022” the phone is ringing. People are asking for more information! Get more insights on how we want to revolutionize the early detection of diseases! Read the Interview of the "Zuger Woche" with Christian Zwicky, CEO of Deep Breath Intelligence.
Smarte Nachtwächter
More than 936 million people worldwide suffer from obstructive sleep apnea - 26 million of them in Germany (as of 2019 /source: ResMed GmbH & Co. KG) and more than 150,000 people in Switzerland (source: Lungenliga Schweiz).
The article "Smarte Nachtwächter" on this topic was published in the "NZZ am Sonntag" on March 13, 2022. Read how creative and visionary Swiss companies and clinics are working and researching on non-invasive solutions to help patients. Have you heard about potential solutions, such as Sleepiz's apnea screening? Or of the identification of specific metabolic molecules in the breath, a method that is being further developed by us, Deep Breath Intelligence? Read the opinion of Prof. Dr. Malcolm Kohler, Clinical Director of the Department of Pulmonology, University Hospital Zurich, on these developments.
DBI, the „Young Guns“ in „Escher“ magazine
We at DBI are proud that our software and data science solutions for evaluating molecular breath analysis to improve people’s health has been noticed as particularly observable and innovative in Switzerland. Deep Breath Intelligence made it to the cover of the “Escher” magazine! Furthermore, we are one of the selected companies in the category "Young Guns" in the Watchlist 2022 of the "Escher”.
Read the interview with Christian Zwicky, CEO of DBI:
Interview Christian Zwicky, CEO DBI
The complete Watchlist 2022 can be found here:
SRF Schweizer Radio und Fernsehen broadcast on DBI`s technology for Covid19 diagnosis
DBI`s CEO, Christian Zwicky was interviewed for Tagesschau at SRF (Schweizer Radio und Fernsehen) about our breath technology and analysis for Covid19 and other diseases.
Check out the broadcast!
Tagesschau 30.7.2021 SRF "Covid-Atem-Test"
